{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:57:49Z","timestamp":1790906269531,"version":"4.1.0"},"reference-count":56,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Delivery"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1080\/20415990.2024.2406226","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T13:57:49Z","timestamp":1727963869000},"page":"829-843","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Role of EYP-1901 in neovascular age-related macular degeneration and diabetic eye diseases: review of Phase I\/II trials"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3787-0838","authenticated-orcid":false,"given":"Abrahem","family":"Sayed","sequence":"first","affiliation":[{"name":"University of Illinois Chicago, Chicago, IL 60607, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8814-0747","authenticated-orcid":false,"given":"Pranesh","family":"Ravichandran","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Illinois College of Medicine, Peoria, IL 61605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1387-1249","authenticated-orcid":false,"given":"Cecilia","family":"Canizela","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Illinois College of Medicine, Peoria, IL 61605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehan M","family":"Hussain","sequence":"additional","affiliation":[{"name":"Retina Health Institute, Algonquin, IL 60102, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S295223"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1077669"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169424"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1636031"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2020.45.7.3127028"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2052042"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-018-0145-7"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2016_22"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042018813512360"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1586\/17469899.2013.840095"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000291"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112436"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/786870"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom12111629"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.01.001"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27165089"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-023-00631-w"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.061237"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.04.021"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S231913"},{"key":"e_1_3_3_23_1","unstructured":"Two-year PULSAR Trial Results for Aflibercept 8mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration. 2023. [cited 2024 Web Page]. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/two-year-pulsar-trial-results-aflibercept-8-mg-demonstrate"},{"key":"e_1_3_3_24_1","unstructured":"Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS. 2023. [cited 2024 Web Page]. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/aflibercept-8-mg-two-year-results-pivotal-photon-trial-diabetic"},{"key":"e_1_3_3_25_1","unstructured":"EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD) Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR). 2023. [cited 2024 Web Page]. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/eylea-hd-aflibercept-injection-8-mg-approved-fda-treatment-wet"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.04.030"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.1"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01909-z"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02610-z"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124018"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1356817"},{"issue":"8","key":"e_1_3_3_32_1","first-page":"931","article-title":"The DAVIO trial: a Phase I, open-label, dose-escalation study of a single injection of EYP-1901 (Vorolanib in Durasert \u00ae Platform) demonstrating reduced treatment burden in wet age-related macular degeneration","volume":"64","author":"Abbey AM","year":"2023","unstructured":"Abbey AM, Patel S, Barakat MR, et al. The DAVIO trial: a Phase I, open-label, dose-escalation study of a single injection of EYP-1901 (Vorolanib in Durasert \u00ae Platform) demonstrating reduced treatment burden in wet age-related macular degeneration. Investigative Ophthalmology & Visual Science. 2023;64(8):931.","journal-title":"Investigative Ophthalmology & Visual Science."},{"key":"e_1_3_3_33_1","unstructured":"Singh RP Peters K Howard-Sparks M et al. A 12-month ocular pharmacokinetic study of EYP-1901 a sustained-release intravitreal formulation of the tyrosine kinase inhibitor Vorolanib. 2023. [cited 2024 Web Page]. Available from: https:\/\/investors.eyepointpharma.com\/static-files\/9536fe51-67dc-4fe4-b0c4-c0707de2aa88"},{"key":"e_1_3_3_34_1","unstructured":"Howard-Sparks M Saim S Farjo R et al. Neuroprotective effect of tyrosine kinase inhibitor vorolanib in a mouse model of retinal detachment.2023. [cited 2024 Web Page]. Available from: https:\/\/investors.eyepointpharma.com\/static-files\/502d269d-0d9c-40a7-a02f-4176a08f16ae"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-7644-7_41"},{"key":"e_1_3_3_36_1","unstructured":"EYP-1901 in wet AMD DAVIO 2 Phase II Clinical Trial Topline Data. 2023. [cited 2024 Web Page]. Available from: https:\/\/investors.eyepointpharma.com\/static-files\/2f2e6f27-26f6-400f-9e52-a3fec5885ea7"},{"key":"e_1_3_3_37_1","volume-title":"pSivida and Ophthalmic Drug Delivery","author":"Ashton P","year":"2024","unstructured":"Ashton P. pSivida and Ophthalmic Drug Delivery:Frederick Furness Publishing Ltd; 2024. Available from: https:\/\/www.ondrugdelivery.com\/wp-content\/uploads\/2018\/02\/Psvidia-HR.pdf"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010469.pub4"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010072"},{"key":"e_1_3_3_40_1","unstructured":"First in human study to evaluate the safety and tolerability of EYP-1901 in patients with wet age related macular degeneration (wAMD). 2023. [cited 2024 Web Page]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04747197#more-information"},{"key":"e_1_3_3_41_1","unstructured":"Wykoff CC. THE DAVIO 2 TRIAL: topline data from a Phase II multicenter study of a single injection of EYP-1901 (Vorolanib in the Durasert E technology) vs Aflibercept for previously treated wet age-related macular degeneration. 2023. [cited 2024 Web Page]. Available from: https:\/\/eyepointpharma.com\/wp-content\/uploads\/2024\/02\/Angiogenesis-2024_DAVIO-2-Topline-Deck_16Jan2024.pdf"},{"key":"e_1_3_3_42_1","unstructured":"Study of EYP-1901 in subjects with wet age related macular degeneration (wAMD). 2024. [cited 2024 Web Page]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05381948"},{"key":"e_1_3_3_43_1","unstructured":"EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase II DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints. 2023. [cited 2024 Web Page]. Available from: https:\/\/investors.eyepointpharma.com\/news-releases\/news-release-details\/eyepoint-pharmaceuticals-announces-positive-topline-data-phase-2"},{"key":"e_1_3_3_44_1","unstructured":"EyePoint Pharmaceuticals Announces Topline Data from the Phase II PAVIA Trial of DURAVYU\u2122 in Non-Proliferative Diabetic Retinopathy. 2024. [cited 2024 Web Page]. Available from: https:\/\/investors.eyepointpharma.com\/news-releases\/news-release-details\/eyepoint-pharmaceuticals-announces-topline-data-phase-2-pavia"},{"key":"e_1_3_3_45_1","unstructured":"EyePoint Pharmaceuticals Announces First Patient Dosed in Phase II VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema. 2024. [cited 2024 Web Page]. Available from: https:\/\/investors.eyepointpharma.com\/news-releases\/news-release-details\/eyepoint-pharmaceuticals-announces-first-patient-dosed-phase-2-1"},{"key":"e_1_3_3_46_1","unstructured":"Study of EYP-1901 in Patients With Diabetic Macular Edema (DME). 2023. [cited 2024 Web Page]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06099184"},{"key":"e_1_3_3_47_1","unstructured":"Phase II VERONA Clinical Trial in Diabetic Macular Edema (DME). [cited 2024 Web Page]. Available from: https:\/\/eyepointpharma.com\/trial\/phase-2-verona-clinical-trial-in-diabetic-macular-edema-dme-2\/"},{"key":"e_1_3_3_48_1","unstructured":"Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR). 2024. [cited 2024 Web Page]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05383209"},{"key":"e_1_3_3_49_1","unstructured":"Phase II PAVIA Clinical Trial in Non-Proliferative Diabetic Retinopathy (NPDR). [cited 2024 Web Page]. Available from: https:\/\/eyepointpharma.com\/trial\/phase-2-pavia-clinical-trial-in-non-proliferative-diabetic-retinopathy-npdr-2\/"},{"key":"e_1_3_3_50_1","unstructured":"EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists. 2024. [cited 2024 Web Page]. Available from: https:\/\/investors.eyepointpharma.com\/news-releases\/news-release-details\/eyepoint-pharmaceuticals-expands-scientific-advisory-board-world"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2113375"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000147"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107358"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00325-5"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.02.001"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.10.008"},{"key":"e_1_3_3_57_1","unstructured":"Kirkner R. A deeper dive into why DAZZLE results of KSI-301 in nAMD \u2018disappointed\u2019. 2022. [cited 2024 Web Page]. Available from: https:\/\/www.retina-specialist.com\/article\/a-deeper-dive-into-why-dazzle-results-of-ksi301-in-namd-disappointed"},{"key":"e_1_3_3_58_1","unstructured":"Kodiak Sciences Announces Top-Line Results from its initial Phase IIb\/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration. Kodiak Sciences Inc.; 2022. Available from: https:\/\/ir.kodiak.com\/news-releases\/news-release-details\/kodiak-sciences-announces-top-line-results-its-initial-phase-2b3"}],"container-title":["Therapeutic Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20415990.2024.2406226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T07:56:14Z","timestamp":1729583774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/20415990.2024.2406226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1080\/20415990.2024.2406226"],"URL":"https:\/\/doi.org\/10.1080\/20415990.2024.2406226","relation":{},"ISSN":["2041-5990","2041-6008"],"issn-type":[{"value":"2041-5990","type":"print"},{"value":"2041-6008","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itde20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itde20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-06-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}